170 filings
Page 7 of 9
6-K
VALN
Valneva SE
27 Oct 21
Valneva Announces Launch of Proposed Global Offering of American Depository Shares and Ordinary Shares
5:00pm
F-1
VALN
Valneva SE
26 Oct 21
Registration statement (foreign)
5:04pm
CORRESP
VALN
Valneva SE
26 Oct 21
Correspondence with SEC
12:00am
CORRESP
VALN
Valneva SE
26 Oct 21
Correspondence with SEC
12:00am
UPLOAD
VALN
Valneva SE
25 Oct 21
Letter from SEC
12:00am
DRS
VALN
Valneva SE
20 Oct 21
Draft registration statement
12:00am
6-K
VALN
Valneva SE
18 Oct 21
Valneva Reports Positive Phase 3 Results for Inactivated, Adjuvanted COVID-19 Vaccine Candidate VLA2001
8:00am
6-K
VALN
Valneva SE
5 Oct 21
Valneva to Present and Hold Investor Meetings at the Guggenheim Vaccines and Infectious Disease Conference
9:30am
6-K
VALN
Valneva SE
29 Sep 21
Valneva and Pfizer Report Further Positive Phase 2 Results, Including Booster Response, for Lyme Disease Vaccine Candidate
9:30am
6-K
VALN
Valneva SE
24 Sep 21
Valneva Continues Expansion of Clinical Trials of its Inactivated COVID-19 Vaccine Candidate VLA2001
5:25pm
6-K
VALN
Valneva SE
17 Sep 21
Valneva Completes Recruitment of Elderly Participants in Phase 3 Trial of its Inactivated COVID-19 Vaccine
5:25pm
6-K
VALN
Valneva SE
13 Sep 21
Valneva Receives Notice of Termination of COVID-19 Vaccine Supply Agreement by UK Government
5:25pm
6-K
VALN
Valneva SE
3 Sep 21
Valneva to Participate in Goldman Sachs Eleventh Annual Biotech Symposium
5:25pm
6-K
VALN
Valneva SE
23 Aug 21
Valneva Commences Rolling Submission to MHRA for its Inactivated, Adjuvanted COVID-19 Vaccine
5:25pm
6-K
VALN
Valneva SE
13 Aug 21
Valneva Initiates Further Phase 3 Clinical Trial for its COVID-19 Vaccine Candidate
5:25pm
6-K
VALN
Valneva SE
10 Aug 21
Valneva Reports H1 2021 Financial Results and Provides Business Update
5:25pm
6-K
VALN
Valneva SE
5 Aug 21
Valneva Announces Positive Phase 3 Pivotal Results for its Single-Shot Chikungunya Vaccine Candidate
5:26pm
6-K
VALN
Valneva SE
2 Aug 21
Valneva Appoints Peter Buhler as Chief Financial Officer
6:00am
6-K
VALN
Valneva SE
23 Jul 21
Valneva and Pfizer Complete Recruitment for Phase 2 Trial of Lyme Disease Vaccine Candidate
6:00am
6-K
VALN
Valneva SE
9 Jul 21
Current report (foreign)
5:25pm